Bone Metabolism in Arginine Vasopressin Deficiency Compared to Primary Polydipsia and Healthy Controls

Overview

This study evaluated bone turnover markers in patients with arginine vasopressin deficiency (AVP-D), primary polydipsia (PP), and healthy controls (HC). Findings revealed that AVP-D patients had reduced bone resorption marker CTX and an increased bone formation index (P1NP/CTX ratio) compared to healthy individuals, with no significant differences observed in PP patients.

Background

Arginine vasopressin (AVP) and oxytocin (OXT) are neurohormones influencing bone metabolism, with AVP generally promoting bone resorption and reducing formation, while OXT has anabolic effects. Patients with AVP deficiency, such as those with central diabetes insipidus, often have concomitant OXT deficiency, but the impact on human bone metabolism remains unclear. Previous studies suggested potential deleterious effects on bone in AVP-D, but data using modern bone turnover markers are limited. This study aimed to clarify bone metabolic status in AVP-D compared to PP and healthy controls using sensitive biochemical markers.

Data Highlights

Key Findings

• Patients with AVP deficiency exhibited significantly lower serum CTX levels, indicating reduced bone resorption, compared to healthy controls.
• The bone formation marker P1NP was similar across AVP-D, PP, and healthy groups.
• The bone formation index (P1NP/CTX ratio) was increased in AVP-D patients, reflecting a relative shift towards bone formation.
• 25OH-vitamin D concentrations were significantly lower in AVP-D patients compared to healthy controls.
• No significant differences in bone turnover markers were observed between primary polydipsia patients and either AVP-D or healthy controls.
• Serum calcium and phosphate levels were comparable among all groups, suggesting stable mineral homeostasis.

Clinical Implications

These findings suggest that AVP deficiency does not lead to major detrimental alterations in bone metabolism, as evidenced by reduced bone resorption and a relative increase in bone formation index. Clinicians should be aware that despite lower vitamin D levels in AVP-D patients, bone turnover markers do not indicate increased bone loss risk. Monitoring bone health in AVP-D should consider these biochemical profiles, and further research may clarify long-term skeletal outcomes.

Conclusion

In summary, AVP deficiency is associated with decreased bone resorption and an increased bone formation index without major adverse effects on bone metabolism markers. This study provides novel insights into bone turnover in AVP-D, contrasting with prior assumptions of deleterious bone effects.

References

1. Pivonello et al 1998 -- Bone metabolism in AVP deficiency
2. Aulinas et al 2021 -- Bone mineral density and oxytocin in AVP-D
3. URANOS Trial NCT05890690 -- Study protocol and design